Blood pressure control and cardiovascular risk in patients of Indo-Asian and African-Caribbean descent

International Journal of Clinical Practice

Volumn 52, Issue 6, 1998, Pages 388-394

  Burden, A C ^a  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT;

ASIAN; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; ETHNIC GROUP; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FAILURE; MORBIDITY; MORTALITY; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; STROKE;

AFRICA; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GREAT BRITAIN; HUMANS; HYPERTENSION; INDIA; INSULIN RESISTANCE; RISK FACTORS; WEST INDIES;

EID: 0031705711     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Howard J, Tiedeman G. The relative effectiveness of antihypertensive drugs in Caucasians and Negroes. Clin Pharmacol Ther 1967; 8: 502-520.
2. Raleigh VS. Diabetes and hypertension in Britain's ethnic minorities: implications for the future of renal services. BMJ 1997; 314: 209-213.
3. Jamerson KA. Prevalence of complications and response to different treatments of hypertension in African-Americans and white Americans in the US. Clin Exp Hypertens 1993; 15: 979-995.
4. Gupta S, de Beider A, O Hughes L. Avoiding premature coronary deaths in Asians in Britain. BMJ 1995; 311: 1035-1036.
5. Lowy AGJ, Woods KL, Botha JL. The effects of demographic shift on CHD mortality in a large immigrant population at high risk. J Pub Health Med 1991; 13: 276-280.
6. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-183.
7. Sever PS, Mackay JA. The hypertension trials. J Hypertens 1996; 14(suppl 2): S29-S34.
8. Grimm RH. Treating hypertension and cardiovascular risk: are there trade-offs? Am Heart J 1990; 119: 729-732.
9. Krone W, Nagele H. Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am Heart J 1988; 116: 1729-1734.
10. Burris JF. Beyond controlling blood pressure in the black patient: metabolic considerations. J Natl Med Assoc 1995; 87: 359-362.
11. Simmons D, Williams DRR, Powell MJ. The Coventry diabetes study: prevalence of diabetes and impaired glucose tolerance in Europids and Asians. Q J Med 1991; 296: 1021-1030.
12. Carter BL, Frohlich ED, Elliott WJ et al. Selected factors that influence responses to antihypertensives. Arch Fam Med 1994; 3: 528-536.
13. Havas S, Fujimoto W, Close N et al. The NHLBI workshop on hypertension in Hispanic Americans, Native Americans, and Asian/Pacific Islander Americans. Pub Health Rep 1996; 111: 451-458.
14. Sowunmi A, Rashid TJ, Akinyinka OO, Renwick AG. Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br J Clin Pharmacol 1995; 40: 489-493.
15. Hardman TC, Croft P, Barlow R et al. Ethnic origin and hypertension-associated alterations in sodium-lithium countertransport kinetics. J Hum Hypertens 1995; 9: 687-689.
16. Chaturvedi N, McKeigue PM, Marmot MG. Resting and ambulatory blood pressure differences in Afro-Caribbeans and Europeans. Hypertension 1993; 22: 90-96.
17. Cruikshank JK. Benefit from controlling blood pressure was understated (letter). BMJ 1996; 312: 376.
18. Williams B. Westernised Asians and cardiovascular disease: nature or nurture? Lancet 1995; 345: 401-402.
19. Wild S, McKeigue P. Cross sectional analysis of mortality by country of birth in England and Wales. BMJ 1997; 314: 705-710.
20. UK Prospective Diabetes Study Group. UK prospective diabetes study XII: differences between Asian. Afro-Caribbean and white Caucasian type 2 diabetic patients at diagnosis of diabetes. Diab Med 1994; 11: 670-677.
21. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
22. Bhatnagar D, Anand IS, Durrington PN et al. Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet 1995; 345: 405-409.
23. National High Blood Pressure Education Working Group. Report on hypertension in diabetes. Hypertension 1994; 23: 145-158.
24. Stephenson JM, Kenny S, Stevens LK. Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diab Med 1995; 12: 149-155.
25. Burden AC, McNally PG, Feehally J, Walls J. Increased incidence of end-stage renal failure secondary to diabetes mellitus in Asian ethnic groups in the United Kingdom. Diab Med 1992; 9: 641-645.
26. Chaturvedi N, McKeigue PM, Marmot MG. The relationship of glucose intolerance to coronary risk in Afro-Caribbeans compared with Europeans. Diabetologia 1994; 37: 765-772.
27. Flack JM, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. Am J Kidney Dis 1993; 4(suppl 1): 31-40.
28. Gottdiener JS, Reda DJ, Materson BJ et al. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. J Am Coll Cardiol 1994; 24: 1492-1498.
29. Mancia G, Omboni S, Parati G, Trazzi S. Twenty-four hour blood pressure monitoring and end-organ damage. Blood Press 1992; Suppl 1: 38-41.
30. Kaplan N. Ethnic aspects of hypertension. Lancet 1994; 344: 450-453.
31. Williams R, Bhopal R, Hunt K. Coronary risk in a British Punjabi population: comparative profile of non-biochemical factors. Int J Epidemiol 1994; 23: 28-37.
32. Butler C, Rollnick S, Stott N. The practitioner, the patient and resistance to change: recent ideas on compliance. Can Med Assoc J 1996; 154: 1357-1362.
33. Chowdhury SGM, Alam MN. A selective alpha receptor antagonist doxazosin in the treatment of essential hypertension. Bangladesh Med J 1991; 20: 85-88.
34. Zubair M, Karim S, Hussain S. Isradipine in Asian patients with hypertension. Drugs 1990; 40: 26-29.
35. Materson BJ, Reda BJ, Cushman WC et al. Department of Veterans Affairs single drug therapy of hypertension study: revised figures and new data. Am J Hypertens 1995; 8: 189-192.
36. Saunders E, Weir M, Kong W et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150: 1707-1713.
37. Manolis AJ, Gavras I, Pieprzak M et al. Isradipine versus captopril in patients with essential hypertension. Clin Ther 1995; 17: 648-655.
38. Weir MR, Gray JM, Paster R et al. Differing mechanisms of action of angiotensin converting enzyme inhibition in black and white hypertensive patients. Hypertension 1995; 25: 124-130.
39. Johnson JA. Racial differences in lymphocyte beta-receptor sensitivity to propranolol. Life Sci 1993; 53: 297-304.
40. Sever P, Beevers G, Bulpitt C et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983-987.
41. Isah AO, Obasohan AO, Oyewo EA et al. Amlodipine versus nifedipine in the treatment of mild-to-moderate hypertension in black Africans. Curr Ther Res 1996; 57: 300-308.
42. Skoularigis J, Strugo V, Weinberg J et al. Effects of amlodipine on 24 hour ambulatory blood pressure profiles, electrocardiographic monitoring and left ventricular mass and function in black patients with very severe hypertension. J Clin Pharmacol 1995; 35: 1052-1059.
43. Newman HF, Marcus H. Erectile dysfunction in diabetes and hypertension. Urology 1985; 26: 135-137.
44. Müller SC. Hypertension and impotence. Eur Urol 1991; 19: 29-34.
45. Konen JC, Curtis LG, Summerson JH. Symptoms and complications of adult diabetic patients in a family practice. Arch Fam Med 1996; 5: 135-145.
46. Grimm RH, Grandits GA, Prineas RJ et al. Long term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8-14.
47. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295-320.
48. Frick MHO, Cox AD, Himanen P et al. Serum lipid changes in a one year, multicenter, double blind comparison of doxazosin and atenolol for mild to moderate essential hypertension. Am J Cardiol 1987; 59: 61G-67G.
49. Feher MD, Henderson AD, Wadsworth J et al. Alpha-blocker therapy: a possible advance in the treatment of diabetic hypertension: results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetics. J Hum Hypertens 1990; 4: 571-577.
50. Shieh SM, Sheu WH, Shen DC et al. Glucose, insulin and lipid metabolism in insulin treated patients with hypertension. Am J Hypertens 1992; 5: 827-831.
51. Ferrara LA, Di Marino L, Russo O et al, on behalf of the DoCHH Study Group. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. Hypertension 1993; 21: 97-104.
52. Levy D, Walmsley P, Levenstein M. Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J 1996; 131: 966-973.
53. Huupponen R, Lehtonen A, Vahatalo M. Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic subjects. Eur J Clin Pharmacol 1992; 43: 365-368.
54. Giordano M, Matsuda M, Sanders L et al. Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 1995; 44: 665-671.
55. Maheux P, Facchini F, Jeppesen J et al. Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin treated patients with hypertension. Am J Hypertens 1994; 7: 416-424.
56. Pollare T, Lithell H, Selinus I et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised double blind study of effects on carbohydrate and lipid metabolism in hypertensive patients. BMJ 1989; 297: 1142-1147.
57. Rabkin SW, Huff MW, Newman C et al. Lipids and lipoproteins during antihypertensive drug therapy: comparison of doxazosin and atenolol in a randomized double blind trial: the Alpha Beta Canada Study. Hypertension 1994; 24: 241-248.
58. Itskovitz HD. Alpha-1 blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. Clin Ther 1994; 3: 490-504.
59. Bressler P, DeFronzo RA. Drugs and diabetes. Diab Rev 1994; 2: 53-84.
60. Pollare T, Lithell H, Berne C et al. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-873.
61. Crepaldi G, Carraro A, Brocco E et al. Hypertension and non-insulin dependent diabetes: a comparison between an angiotensin converting enzyme inhibitor and a calcium antagonist. Acta Diahetol 1995; 32: 203-208.
62. Furberg CD, Psaty BM. Should calcium antagonists be first-line drugs in hypertension? Herz 1995; 20: 365-369.
63. Packer M, O Connor CM, Ghali JK et al, for the Prospective Randomized Amlodipine Survival Evaluation Study Group (PRAISE). Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-1114.
64. Potempa K, Babich K, Fruh S, Foff L. Blood pressure and mood responses in hypertensive patients on antihypertensive medications. J Am Acad Nurse Pract 1993; 5: 211-218.